Philip W Kantoff MD

Hematologic Oncology

CEO and Co-Founder, Convergent Therapeutics

Memorial Sloan Kettering Cancer Center New York1275 York AvenueNew York, NY 10021

Dr. Kantoff is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kantoff's full profile Already have an account?

Summary

Dr. Philip Kantoff is the CEO and Co-Founder of Convergent Therapeutics in Cambridge, Massachusetts. He is a medical oncologist and former Chair of the Department of Medicine at Memorial Sloan-Kettering Cancer Center. He is also the Jerome and Nancy Kohlberg Chair Emeritus at Harvard Medical School. He received his medical degree from The Warren Alpert Medical School of Brown University, his residency at NYU-Bellevue in New York and his fellowship in medical oncology at the Dana-Farber Cancer Institute.

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1987 - 1989
NYU Grossman School of MedicineResidency, Internal Medicine, 1979 - 1983
The Warren Alpert Medical School of Brown UniversityClass of 1979

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 1987 - 2027
NY State Medical License 1979 - 2023
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2013-2015
CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2013-2015
America's Top Doctors Castle Connolly, 2006-2014

Publications & Presentations

PubMed

IDH1 Mutations Are Associated with Favorable Outcomes in Prostate Cancer.
Luka Cavka, Subhiksha Nandakumar, Qingqing Wu, Nihar J Mehta, Zeynep Irem Ozay
European Urology. 2026-05-13
3 citations
Identifying Patients at Risk of Early Lethal Prostate Cancer by Integrating Family History, Polygenic Risk Score, Rare Variants in DNA Repair Genes, and Lifestyle Fact...
Zhizhu Zhang, Yiwen Zhang, Konrad H Stopsack, Adam S Kibel, Edward L Giovannucci
European Urology Oncology. 2026-04-01
Long-term performance of the Gleason score in predicting metastatic and fatal prostate cancer.
Zhike Lin, Konrad H Stopsack, Michelangelo Fiorentino, J Bailey Vaselkiv, Travis Gerke
American Journal of Epidemiology. 2026-03-17

Journal Articles

Association of Genetic Variation of the Six Gene Prognostic Model for Castration‐Resistant Prostate Cancer with Survival
Mark M Pomerantz, Philip W Kantoff, The Prostate
A Dose Finding Clinical Trial of Cabozantinib (XL184) Administered in Combination with Abiraterone Acetate in Metastatic Castration‐Resistant Prostate Cancer
Christopher Sweeney, Lauren C Harshman, Mark Pomerantz, Brandon Bernard, Atish D Choudhury, Philip W Kantoff, The Prostate

Lectures

16th Biennial Urologic Cancer Course
Harvard Medical School, Boston, Massachusetts - 10/11/2012

Other

Clinical presentation and diagnosis of prostate cancer
Kantoff PW, Smith JA, Taplin M
http://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-prostate-cancer
UpToDate, Wolters Kluwer Health - 2013-02-05
Initial staging and evaluation of men with newly diagnosed prostate cancer
Kantoff PW, Smith JA, Taplin M
http://www.uptodate.com/contents/initial-staging-and-evaluation-of-men-with-newly-diagnosed-prostate
UpToDate, Wolters Kluwer Health - 2013-02-05
Initial risk-stratified treatment for advanced testicular germ cell tumors
Kantoff PW, Gilligan TD
http://www.uptodate.com/contents/initial-risk-stratified-treatment-for-advanced-testicular-germ-cell
UpToDate, Wolters Kluwer Health - 2012-09-17

Authored Content

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-Resistant Prostate Cancer in the Era of Precision OncologyApril 2018

Press Mentions

Rana R. McKay, MD: Developing Clinical Trials to Answer Questions Raised in PracticeApril 20th, 2022
POINT Biopharma Global : Convergent Therapeutics and Point Biopharma Announce a Collaboration to Evaluate CONV 01-Α (Rosopatamab-225Ac) in Combination with PNT2002 for Progressive mCRPCSeptember 14th, 2021
Ziopharm Finds New CEO After Six-Month Search; CFO Transition at Lonza to Take Place in DecemberSeptember 3rd, 2021

Grant Support

Df/Hcc Spore In Prostate CancerNational Cancer Institute2007–2011
Developmental Research ProgramNational Cancer Institute2007–2011
Career Development ProgramNational Cancer Institute2007–2011
Administration, Evaluation, And Planning CoreNational Cancer Institute2007–2011
Molecular Signatures Of Lethal An Indolent Prostate CancerNational Cancer Institute2007–2009